PI3Kδ Inhibition Augments the Efficacy of Rapamycin in Suppressing Proliferation of Epstein−Barr Virus (EBV)+ B Cell Lymphomas

Syk-Induced Phosphatidylinositol-3-Kinase Activation in Epstein-Barr Virus Posttransplant Lymphoproliferative Disorder

(2013) O. Hatton et al.   AMERICAN JOURNAL OF TRANSPLANTATION

mTOR inhibitors in cancer therapy

(2012) Yekaterina Y. Zaytseva et al.   CANCER LETTERS

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009

(2012) Pierluca Piselli et al.   EUROPEAN JOURNAL OF CANCER

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

(2012) Antonella De Luca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation

(2012) Niki Tzenaki et al.   FASEB JOURNAL

Src Kinase and Syk Activation Initiate PI3K Signaling by a Chimeric Latent Membrane Protein 1 in Epstein-Barr Virus (EBV)+ B Cell Lymphomas

(2012) Olivia Hatton et al.   PLoS One

Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies

(2012) Kamal D. Puri et al.   Frontiers in Immunology

PI3K  inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

(2011) S. A. Meadows et al.   BLOOD

Syk Activation of Phosphatidylinositol 3-Kinase/Akt Prevents HtrA2-dependent Loss of X-linked Inhibitor of Apoptosis Protein (XIAP) to Promote Survival of Epstein-Barr Virus+ (EBV+) B Cell Lymphomas

(2011) Olivia Hatton et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

PI3K/p110  is a novel therapeutic target in multiple myeloma

(2010) H. Ikeda et al.   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Conversion to Rapamycin Immunosuppression for Malignancy After Kidney Transplantation

(2010) M. Manuelli et al.   TRANSPLANTATION PROCEEDINGS

Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth

(2009) James J. Gibbons et al.   SEMINARS IN ONCOLOGY

mTOR, Cancer and Transplantation

(2008) Edward K. Geissler et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Incidence of PTLD in Pediatric Renal Transplant Recipients Receiving Basiliximab, Calcineurin Inhibitor, Sirolimus and Steroids

(2008) R. A. McDonald et al.   AMERICAN JOURNAL OF TRANSPLANTATION

EBV Latent Membrane Protein 1 Effects on Plakoglobin, Cell Growth, and Migration

(2008) K. H.Y. Shair et al.   CANCER RESEARCH

Epstein–Barr virus, rapamycin, and host immune responses

(2008) Sheri M Krams et al.   Current Opinion in Organ Transplantation